Erectile Dysfunction Treatment Market, by Product (Viagra (Sildenafil citrate), Cialis(Tadalafil), Stendra/Sperda, Levitra/Staxyn, Zydena (Udenafil), and Vitaros (Alprostadil Cream)), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
- Report code : CMI6200 |
- Industry :
Pharmaceutical
- Published On : Nov 2019 |
- Pages : 171 Pages |
- Format :
Erectile Dysfunction: A Prominent Age Related Disorder
Erectile dysfunction (ED) is the recurrent inability to reach or to maintain a penile erection sufficient during sexual activities. It is one of the most common male sexual health disorder. It affects physical and psychosocial health and significantly impacts on the sexual life of patients and their partners. The main symptom of the condition is the inability to attain or maintain firm erection during sexual intercourse. Erectile dysfunction can be classified in two types psychogenic and organic.
The global erectile dysfunction treatment market was valued at US$ 4,946.2 million in 2018, and is expected to exhibit a CAGR of 6.2% over the forecast period (2019 – 2027).
Figure 1. Global Erectile Dysfunction Treatment Market Share (%), By Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Manufacturers are focused on production of generic versions of drugs, owing to expiry of drug patents
Expiry of drug patents have led companies to focus on manufacturing generic versions of drugs for erectile dysfunction. For instance, Eli Lilly’s drug, Cialis, lost patent protection in September 2018. In October 2018, Teva Pharmaceutical launched a generic version of Cialis in the U.S., which is used for treatment of erectile dysfunction. Moreover, in March 2019, Dr. Reddy's Laboratories launched a generic version of Cialis (Tadalafil) tablets, in the U.S. market. Furthermore, in December 2017, Pfizer Inc. launched a generic version of Viagra, Sildenafil Citrate, for treatment of erectile dysfunction. Furthermore, in November, 2018, Alembic Pharmaceuticals launched an AB-rated generic version of Bayer’s Staxyn (vardenafil) orally disintegrating tablet for the treatment of ED.
Adoption of inorganic strategies by key players is expected to propel the global erectile dysfunction treatment market growth over the forecast period
Key players are focused on expansion of their erectile dysfunction product portfolio through various strategies such as collaborations, merger and acquisitions. For instance, in July 2019, Pfizer Inc., merged with Mylan for its off-patent drugs division (Upjohn), which includes Viagra (an erectile dysfunction drug), and Lipitor (a cholesterol treating drug).
Increasing prevalence of erectile dysfunction is expected to drive the global erectile dysfunction treatment market growth
Erectile dysfunction is a condition related to age and secondary medical conditions such as diabetes, hypertension, dyslipidemia, depression, and cardiovascular disease. For instance, in 2015, a study was conducted by the Canadian Institute of Health Research on 4,000 Canadian men aged between 40 to 88 years. The result of the study showcased that out of 4,000 Canadian men, 50% of them suffered with erectile dysfunction. ED is more prevalent in men with cardiovascular disease, and diabetes. Such increasing prevalence of erectile dysfunction is expected to increase demand for the drugs used in ED treatment, which is expected to drive the global erectile dysfunction treatment market growth over the forecast period.
Global Erectile dysfunction market – Regional Insights
Based on region, the global erectile dysfunction treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in global erectile dysfunction treatment market over the forecast period, owing to increasing prevalence of erectile dysfunction and presence of key players in North America region. For instance, in June 2018, according to the Cleveland Clinic Foundation, 617,715 people reported to have erectile dysfunction in the U.S. and this is expected to increase the demand of drugs used for ED treatment, which is expected to drive the global erectile dysfunction treatment market growth. Moreover, key players such as Pfizer Inc, Eli Lilly and Company, and others are present in North America region, these manufacturers are engaged in manufacturing products for ED treatment, which is expected to boost the global erectile dysfunction treatment market growth.
Europe is also expected to witness a significant growth over the forecast period, owing to increasing prevalence of erectile dysfunction. For instance, according to the NCBI, in March 2019, overall prevalence of erectile dysfunction in Germany was 25.2% (among which 3.1% was severe, 9.2% was moderate, 8.7% was mild, and 4.2% was mild to moderate). These factors are expected to drive global erectile dysfunction treatment market growth over the forecast period.
Figure 2: Global Erectile Dysfunction Treatment Market Share (%), By Region, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Restraints
Factors restraining the global erectile dysfunction treatment market are the availability of the alternative treatments such as natural remedies, herbal Viagra, devices used for treating ED, surgical replacements, and others.
Key Players
Key players operating in the global erectile dysfunction treatment market include Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG, Dr. Reddys Laboratories Ltd, and Dong-A Pharmaceutical Co., Ltd.
Erectile dysfunction is a sexual disorder characterized by the inability of a male individual to develop and maintain an erection of the penis during coitus. Sometimes, it is referred as ‘impotence’. In penile erection muscles in the penis relax, and blood flow is increased through penile arteries, this blood is filled in two chambers inside the penis called corpora cavernosa and then the penis becomes rigid. However in erectile dysfunction the blood flow in the penis is inadequate. Erectile dysfunction is not a permanent problem, it can also happen in some cases stress, depression, anxiety and other health conditions can cause erectile dysfunction.
Market Dynamics
Increasing product launches and product approvals for the treatment of erectile dysfunction is expected to boost the global erectile dysfunction treatment market growth. For instance, in November 2018, Zydus Cadila launched generic version of Vardenafil Hydrochloride tablets for the treatment of erectile dysfunction in the U.S. market.
Manufactures are focused on product innovation and product launches, in order to meet the unmet medical needs for ED treatment. For instance, in August 2014, Sandoz, the generic pharmaceuticals division of Novartis launched topical therapy ‘Vitaros’ in Sweden, an innovative new therapy for erectile dysfunction. Vitaros, is an innovative new topical therapy for treatment of erectile dysfunction (ED). It is easy to use and has rapid onset of action.
Increasing prevalence of erectile dysfunction is expected to drive the global erectile dysfunction treatment market growth. For instance, according to the Massachusetts Male Aging Study (MMAS) 2018, the incidence of erectile dysfunction in Massachusetts U.S. was 52%, the study showed that prevalence of ED increases with age. Around 40% men were affected at the age 40 and about 70% men were affected at the age 70. In a cohort study by the MMAS, it was observed that one in four men seek medical help for treating erectile dysfunction is above 40 years of age, among them 50% were diagnosed with severe erectile dysfunction.
Key features of the study:
- This report provides in-depth analysis of the global erectile dysfunction treatment market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period: 2019 – 2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global erectile dysfunction treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.
- Key companies covered as a part of this study include Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG, Dr. Reddys Laboratories Ltd, and Dong-A Pharmaceutical Co., Ltd
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, end user upgrades, market expansion, and marketing tactics
- The global erectile dysfunction treatment market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers for erectile dysfunction products, research and consulting firms, new entrants, and financial analysts
- Various strategy matrices used in analyzing the erectile dysfunction market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Erectile Dysfunction Treatment Market, By Product:
- Viagra (Sildenafil citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- Global Erectile Dysfunction Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global Erectile Dysfunction Treatment Market, By Region:
- North America
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.S.
- Canada
- By Product:
- Europe
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- By Product:
- Asia Pacific
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- By Product:
- Latin America
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product:
- Middle East
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product:
- Africa
- By Product:
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Spedra
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- By Product:
- North America
- Company Profiles
- Mylan Pharmaceuticals Inc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments
- Strategies
- Cipla Ltd
- Aurobindo Pharma Ltd
- Eli Lily & Co
- Novartis International AG
- Torrent Pharmaceuticals Ltd
- Pfizer Inc
- Bayer Pharma AG
- Reddys Laboratories Ltd
- Dong-A Pharmaceutical Co., Ltd
- Mylan Pharmaceuticals Inc*
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Supply Side Drivers
- Demand Side Drivers
- Economic Drivers
- Restraints
- Market Opportunities
- Drivers
- PEST Analysis
- Campaigns and Programs
- Pipeline Drugs
- Prevalence and Incidence
- Market Dynamics
- Global Erectile Dysfunction Treatment Market, By Product, 2016 - 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 - 2027
- Segment Trends
- Viagra (Sildenafil Citrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Cialis (Tadalafil)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
- Segment Trend
- Stendra/Sperda
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
- Segment Trend
- Levitra/Staxyn
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
- Segment Trend
- Zydena (Udenafil)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
- Segment Trend
- Vitaros (Alprostadil Cream)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
- Segment Trend
- Introduction
- Global Erectile Dysfunction Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 - 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Erectile Dysfunction Treatment Market, By Country, 2016 - 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Country, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Country, 2017 – 2027
- North America
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Mylan Pharmaceuticals Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Cipla Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Aurobindo Pharma Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Eli Lily & Co
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Torrent Pharmaceuticals Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Pfizer Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Bayer Pharma AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Dr. Reddys Laboratories Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Dong-A Pharmaceutical Co., Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Mylan Pharmaceuticals Inc
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 33 market data tables and 26 figures on "Erectile Dysfunction Treatment Market - Global forecast to 2027”.
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.